← board
GUTS
distress 9/10 · high distress / dilution risk$0.78+3%today-67% from 52w high
Lead: obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$63M
Runway
0.7 yrs
Shares 1y
+215%
Price & events
-62.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.6%
1D
-8.9%
1W
-6.0%
1M
+33.9%
3M
-62.8%
6M
-59.5%
1Y
-80.8%
2Y
—
5Y
-93.9%
All
Overview
- Market Cap
- $123.38M
- Volume
- 231.21K
- 52 Week Range
- $0.39 – $2.37
- Total Shares
- 158.65M
- Float Shares
- 143.27M
- Short %
- 1.56%
- % Held by Insiders
- 1.35%
- % Held by Institutions
- 52.42%
- RVOL
- 0.13x
- Beta
- 2.29
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Upcoming readouts & decisions · our signals
2 upcoming events have our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 22
- second half of 2026Guided 55%trial initiationsecondaryPhase 1/2RJVA-001 · First-in-human dosing and preliminary data expectedSEC 8-K
- 2026Guided 40%readoutPhase 1RJVA-001 · Preliminary clinical data from first-in-human studySEC 8-K
- late Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)Revita · De Novo marketing application submission to FDASEC 8-K
- early Q4 2026Guided 70%readoutPhase 3Revita · Topline six-month randomized data from REMAIN-1 Pivotal CohortSEC 8-K
- Q3 2026Guided 70%readoutPhase 3Revita · One-year randomized data from REMAIN-1 Midpoint CohortSEC 8-K
- third quarter of 2026Guided 70%filing acceptanceFiled (NDA/BLA)RJVA-001 · Regulatory feedback expected on Australian CTASEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutRevita · 1-year REVEAL-1 Cohort dataSEC 8-K
- 2026-05-11fda agreementRJVA-001 · Received Clinical Trial Application authorization in Netherlands to initiate Phase 1/2 studySEC 8-K
- early 2026enrollment completesecondaryRevita · Complete randomizations for REMAIN-1 Pivotal CohortSEC 8-K
- Q1 2026readoutRevita · 6-month data from REMAIN-1 Midpoint CohortSEC 8-K
- early 2026trial initiationsecondaryRevita · Randomization of REMAIN-1 Pivotal CohortSEC 8-K
- 2026-03-24fda agreementRevita · FDA pre-submission feedback acknowledged safety profile consistent with Class II device classification for De Novo pathway.SEC 8-K
- starting in January 2026readoutPhase 3Key data readouts anticipated starting in January 2026.SEC 8-K
- summer 2025enrollment completesecondaryRevita · Full enrollment of REMAIN-1 pivotal studySEC 8-K
- Q3 2025readoutPhase 3Revita · REMAIN-1 Midpoint Cohort dataSEC 8-K
- June 2025readoutRevita · REVEAL-1 Cohort open-label dataSEC 8-K
- by June 2025regulatory submissionFiled (NDA/BLA)RJVA-001 · First CTA module submissionSEC 8-K
- Q1 2025conferencedata presentationsecondaryRevita · Data from REVEAL-1 cohort to be presentedSEC 8-K
- 2025-01-31trial discontinuedRevita · Paused investment in Revita type 2 diabetes programs (REVITALIZE-1 study and German Real-World Registry).SEC 8-K
- Q4 2024readoutRevita · open-label study data readout in weight maintenanceSEC 8-K
- November 5, 2024 at ObesityWeek 2024conferencedata presentationsecondaryRJVA-001 · Oral presentation of new preclinical data on sustained weight maintenance and blood sugarSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $5 (+547% upside) · 6 analysts
- 2026-07-01Craig-HallumBuy
- 2026-06-04HC Wainwright & Co.Buy
- 2026-04-24HC Wainwright & Co.Buy
- 2026-03-26Canaccord GenuityBuy
- 2026-01-30Morgan StanleyOverweight → Equal-Weight
- 2025-12-02HC Wainwright & Co.Buy
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-22Fractyl Health to Participate in Upcoming Investor Events - Yahoo Finance
- 2026-07-22Fractyl Health CEO to Join Meetings and Aug. 12 Fireside Chat - Stock Titan
- 2026-07-21Lagos Market Fire Guts 17 Shops - Channels Television
- 2026-07-21Legal actions loom after Trump administration guts wildlife protections - KRWG Public Media
- 2026-07-20State guts Town’s ban on Use Variances - My Southborough
- 2026-07-20Trump Guts Federal Election Agency Months Before 2026 Midterms - Jacksonville Free Press
- 2026-07-20Trump Administration Further Guts Endangered Species Act Implementation With Two New Rules - CleanTechnica
- 2026-07-20Fractyl Health (GUTS) AGM 2026 Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.